Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
The S&P/ASX 200 (INDEXASX:XJO) finished at an all-time high on Thursday. Wesfarmers (ASX:WES) shares are making headlines.
The Mesoblast Limited (ASX:MSB) share price is under the spotlight after revealing its quarterly update to investors.
The Mesoblast Limited (ASX: MSB) share price jumped as high as 12% today on results for the third quarter (Q3). What else is rocketing the Mesoblast share price upwards?
The Mesoblast Limited (ASX:MSB) share price is under scrutiny today after making an announcement about a strategic investor and the placement.
The Mesoblast Limited (ASX:MSB) share price will be on watch this week with a capital raising and the release of the FY21 half-year result.
The Mesoblast Limited (ASX:MSB) share price is up 5% after making a trial announcement.
The Mesoblast Limited (ASX:MSB) share price is going nuts again today after giving an update.
The S&P/ASX 200 (INDEXASX:XJO) is set to open higher on Monday. A2 Milk Company (ASX:A2M) and Mesoblast (ASX:MSB) shares are in the news.
The Mesoblast Limited (ASX:MSB) share price has plunged 43% after giving an update about its COVID-19 ARDS trial.
